{"id":10154,"date":"2020-12-02T21:59:58","date_gmt":"2020-12-02T12:59:58","guid":{"rendered":"http:\/\/cell.brc.riken.jp\/en\/?page_id=10154"},"modified":"2025-08-25T14:01:23","modified_gmt":"2025-08-25T05:01:23","slug":"diseaselist_3","status":"publish","type":"page","link":"http:\/\/cell.brc.riken.jp\/en\/hps\/patient_specific_ips\/diseaselist_3","title":{"rendered":"Skin and connective tissue diseases"},"content":{"rendered":"

\uff0a When you want to use some Disease-specific iPS cells, please e-mail to the following address.
\n\uff0a In relation to the information that are not described below, please e-mail to the following address.<\/p>\n

Contact us :\u00a0cellips.brc\"\"riken.jp<\/a><\/p>\n

Blue letter cells are available. You obtain the information by clicking the blue letter.
\n*iPS cells created using the Sendai virus vector are now available<\/a><\/p>\n

*Terms:
\nIn relation to all iPS cell lines, approval of institutional review board and\/or institutional ethical committee regarding the research using iPS cells is necessary.
\nIn relation to all iPS cell lines, commercial use is prohibited.
\nIn relation to the cell lines marked with \u25ce, (1) the recipient does not need to obtain an approval from the depositor, (2) there is no need of collaboration with the depositor, and (3) for-profit entities can also utilize.<\/p>\n

Update : 2020.11.27<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Name of diseases<\/th>\nPatient No.<\/th>\n*Terms<\/th>\nApproval Form<\/th>\nHPS<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\nReferences<\/th>\n<\/tr>\n
Skin and connective tissue diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1. Neurofibromatosis<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Neurofibromatosis type1 (NF1)<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1312<\/a><\/td>\nHPS1313<\/td>\nHPS1314<\/td>\nHPS1315<\/td>\nHPS1316<\/td>\nHPS1317<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2250<\/a><\/td>\nHPS2251<\/td>\nHPS2252<\/td>\nHPS2253<\/td>\nHPS2254<\/td>\nHPS2255<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Neurofibromatosis type2 (NF2)<\/td>\n<\/a>1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2274<\/a><\/td>\nHPS2275<\/td>\nHPS2276<\/td>\nHPS2277<\/td>\nHPS2278<\/td>\nHPS2279<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2. Pemphigus<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Pemphigus, pemphigus vulgaris<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1210<\/a><\/td>\nHPS1211<\/td>\nHPS1212<\/td>\nHPS1213<\/td>\nHPS1214<\/td>\nHPS1215<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1228<\/a><\/td>\nHPS1229<\/td>\nHPS1230<\/td>\nHPS1231<\/td>\nHPS1232<\/td>\nHPS1233<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
3<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2648<\/td>\nHPS2649<\/td>\nHPS2650<\/td>\nHPS2651<\/td>\nHPS2652<\/td>\nHPS2653<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Pemphigus, pemphigus foliaceus<\/td>\n<\/a>1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1325<\/a><\/td>\nHPS1326<\/td>\nHPS1327<\/td>\nHPS1328<\/td>\nHPS1329<\/td>\nHPS1330<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
3. Pustular psoriasis<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Pustular psoriasis, generalized pustular psoriasis<\/td>\n<\/a>1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS3266<\/td>\nHPS3267<\/td>\nHPS3268<\/td>\nHPS3269<\/td>\nHPS3270<\/td>\nHPS3271<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
4. Stevens-Johnson syndrome (SJS)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Stevens-Johnson syndrome (SJS)<\/td>\n<\/a>1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2828<\/a><\/td>\nHPS2829<\/td>\nHPS2830<\/td>\nHPS2831<\/td>\nHPS2832<\/td>\nHPS2833<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
5. Systemic sclerosis (SSc)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Systemic sclerosis (SSc)<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS0178*<\/a><\/td>\nHPS0179*<\/a><\/td>\nHPS0180*<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n<\/td>\n<\/td>\nHPS0184*<\/a><\/td>\nHPS0185*<\/a><\/td>\nHPS0186*<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
3<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1216<\/td>\nHPS1217<\/td>\nHPS1218<\/td>\nHPS1219<\/td>\nHPS1220<\/td>\nHPS1221<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
4<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1240<\/td>\nHPS1241<\/td>\nHPS1242<\/td>\nHPS1243<\/td>\nHPS1244<\/td>\nHPS1245<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
5<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1258<\/td>\nHPS1259<\/td>\nHPS1260<\/td>\nHPS1261<\/td>\nHPS1262<\/td>\nHPS1263<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
6<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1409<\/td>\nHPS1410<\/td>\nHPS1411<\/td>\nHPS1412<\/td>\nHPS1413<\/td>\nHPS1414<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/a>7<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2168<\/td>\nHPS2169<\/td>\nHPS2170<\/td>\nHPS2171<\/td>\nHPS2172<\/td>\nHPS2173<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
6. Congenital ichthyosis<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Congenital ichthyosis, ichthyosis syndrome<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2006<\/td>\nHPS2007<\/td>\nHPS2008<\/td>\nHPS2009<\/td>\nHPS2010<\/td>\nHPS2011<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
7. Pemphigoid<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Pemphigoid (including epidermolysis bullosa acquisita)<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1331<\/td>\nHPS1332<\/td>\nHPS1333<\/td>\nHPS1334<\/td>\nHPS1335<\/td>\nHPS1336<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Pemphigoid (including epidermolysis bullosa acquisita), BP180 antibody positive<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2078<\/td>\nHPS2079<\/td>\nHPS2080<\/td>\nHPS2081<\/td>\nHPS2082<\/td>\nHPS2083<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2983<\/td>\nHPS2984<\/td>\nHPS2985<\/td>\nHPS2986<\/td>\nHPS2987<\/td>\nHPS2988<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
8. Ehlers-Danlos syndrome<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Ehlers-Danlos syndrome, Kosho type<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS0214*<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Ehlers-Danlos syndrome, vascular type<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1650<\/td>\nHPS1651<\/td>\nHPS1652<\/td>\nHPS1653<\/td>\nHPS1654<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Ehlers-Danlos syndrome, type 4 \/ mutation in COL3A1<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2301<\/td>\nHPS2302<\/td>\nHPS2303<\/td>\nHPS2304<\/td>\nHPS2305<\/td>\nHPS2306<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

\uff0a When you want to use some Disease-specific iPS cells, please e-mail to the following address. \uff0a In relation to the information that are not described below, please e-mail to the following address. Contact us :\u00a0cellips.brcriken.jp Blue letter cells are available. You obtain the information by clicking the blue letter. *iPS cells created using the Sendai virus vector are now available *Terms: In relation to all iPS cell lines, approval of institutional review board and\/or institutional ethical committee regarding the research using iPS cells is necessary. In relation to all iPS cell lines, commercial use is prohibited. In relation to the cell lines marked with \u25ce, (1) the recipient does not need to obtain an approval from the depositor, (2) there is no need of collaboration with the depositor, and (3) for-profit entities can also utilize. Update : 2020.11.27 Name of diseases Patient No. *Terms Approval Form HPS References Skin and connective tissue diseases 1. Neurofibromatosis Neurofibromatosis type1 (NF1) 1 \u25ce Unnecessary HPS1312 HPS1313 HPS1314 HPS1315 HPS1316 HPS1317 2 \u25ce Unnecessary HPS2250 HPS2251 HPS2252 HPS2253 HPS2254 HPS2255 Neurofibromatosis type2 (NF2) 1 \u25ce Unnecessary HPS2274 HPS2275 HPS2276 HPS2277 HPS2278 HPS2279 2. Pemphigus Pemphigus, pemphigus vulgaris 1 \u25ce Unnecessary HPS1210 HPS1211 HPS1212 […]<\/p>\n","protected":false},"author":15,"featured_media":0,"parent":10124,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"both","_seopress_redirections_param":"","_seopress_redirections_type":301,"_seopress_analysis_target_kw":"","footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-10154","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/comments?post=10154"}],"version-history":[{"count":2,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10154\/revisions"}],"predecessor-version":[{"id":10190,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10154\/revisions\/10190"}],"up":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10124"}],"wp:attachment":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/media?parent=10154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}